GILL SIMBA
CIK: 0001180763
Associated companies
Transaction History
| FHTX | ▼ Sell | Gift | 47,939 | $0 | 9/13/2022 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 82,000 | $60K | 9/12/2022 | View on chart |
| FHTX | ▼ Sell | Gift | 47,939 | $0 | 9/13/2022 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 82,000 | $60K | 9/12/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Foghorn and Lilly halt FHD-909 development
Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.
Foghorn and Lilly halt FHD-909 development. Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.